This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Radiopeptide Imaging and Therapy in Europe
- Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
- Patient-Specific Dosimetry Calculations Using Mathematic Models of Different Anatomic Sizes During Therapy with 111In-DTPA-D-Phe1-Octreotide Infusions After Catheterization of the Hepatic Artery
- Long-Term Efficacy of Radionuclide Therapy in Patients with Disseminated Neuroendocrine Tumors Uncontrolled by Conventional Therapy
- 110mIn-DTPA-D-Phe1-Octreotide for Imaging of Neuroendocrine Tumors with PET
- Tumor Response After [90Y-DOTA0,Tyr3]Octreotide Radionuclide Therapy in a Transplantable Rat Tumor Model Is Dependent on Tumor Size
- Peptide Receptor Imaging and Therapy
- Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model
- In Vivo Localization of [111In]-DTPA-D-Phe -Octreotide to Human Ovarian Tumor Xenografts Induced to Express the Somatostatin Receptor Subtype 2 Using an Adenoviral Vector
- Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors